Spyre Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Spyre Therapeutics, Inc. on May 30, 2024. The filing serves as a Regulation FD disclosure to update shareholders on the company's capital structure following the effectiveness of the conversion of its Series B Non-Voting Convertible Preferred Stock.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on share count updates.
- Common Stock Outstanding (as of May 29, 2024): 50,782,384 shares
- Pro Forma Common Stock Outstanding: Approximately 65.3 million shares
- Pro Forma Basis: Includes full conversion of Series A and Series B Non-Voting Convertible Preferred Stock, excluding beneficial ownership limitations.
Material Changes
The primary material change is the increase in the number of outstanding shares of Common Stock resulting from the conversion of Series B Preferred Stock. This update follows a previous disclosure on May 15, 2024, regarding the conversion event.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed in this report other than the note that beneficial ownership limitations may restrict the ability of certain preferred stockholders to convert their shares at this time.
Investor Verification Checklist
- Verify the exact conversion ratio and terms for Series A and Series B Preferred Stock in prior filings.
- Confirm the impact of the increased share count on existing shareholder dilution.
- Review the May 15, 2024 Form 8-K for the initial announcement of the Series B conversion.
- Check for any beneficial ownership limitations that may prevent the full 65.3 million pro forma share count from being realized immediately.